Use of sodium–glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 European Society of Cardiology (ESC) guidelines and the 2019 American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) consensus report in a national population of patients with type 2 diabetes
Authors' conclusion
In this nationwide study, the proportion of patients with type 2 diabetes who were recommended treatment with an SGLT2 inhibitor or a GLP-1 receptor agonist was approximately 80% according to the 2019 ESC guidelines and around half according to the 2019 ADA/EASD consensus report. Uptake of these recommendations in routine clinical practice was limited.
Study context
- Population
- Patients with T2DM in the Swedish National Diabetes Register (2020–21)
- Participants
- 435,000 patients
- Exposure
- 2019 ESC guidelines vs 2019 ADA/EASD consensus report
- Outcome
- Treatment eligibility for, and received treatment with, SGLT2 inhibitors and GLP-1 receptor agonists
Methodological detailsnationwide, Swedish National Diabetes Register
- Nationwide
- Swedish National Diabetes Register
Main finding
As reported in the abstract
Recommended any of the two drugs
Recommended any of the two drugs
SGLT2 inhibitors
SGLT2 inhibitors or GLP-1 receptor agonists 2019 ESC guidelines 40.9%
GLP-1 receptor agonists
Observational data: associations, not effects.
Further findings
Received recommended treatment (among those recommended)
Original publication
Use of sodium–glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes. Eur J Prev Cardiol. Published 30 December 2022. doi:10.
Summarised from the published abstract; every number is checked against it